| Direct tumor damage mechanisms of photodynamic therapy. D Nowis, M Makowski, T Stokłosa, M Legat, T Issat, J Gołąb Acta Biochimica Polonica 52 (2), 339-352, 2005 | 462 | 2005 |
| BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance M Koptyra, R Falinski, MO Nowicki, T Stoklosa, I Majsterek, ... Blood 108 (1), 319-327, 2006 | 373 | 2006 |
| BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species–dependent DNA double-strand breaks MO Nowicki, R Falinski, M Koptyra, A Slupianek, T Stoklosa, E Gloc, ... Blood 104 (12), 3746-3753, 2004 | 306 | 2004 |
| Immunologia J Gołąb, W Lasek, DA Nowis, T Stokłosa, WN PWN PWN, 2023 | 263 | 2023 |
| Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity D Nowis, M Legat, T Grzela, J Niderla, E Wilczek, GM Wilczynski, ... Oncogene 25 (24), 3365-3374, 2006 | 234 | 2006 |
| Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors M Nieborowska-Skorska, PK Kopinski, R Ray, G Hoser, D Ngaba, S Flis, ... Blood, The Journal of the American Society of Hematology 119 (18), 4253-4263, 2012 | 211 | 2012 |
| Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice W Feleszko, I Młynarczuk, EZ Bałkowiec-Iskra, A Czajka, T Switaj, ... Clinical Cancer Research 6 (5), 2044-2052, 2000 | 186 | 2000 |
| Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 M Winiarska, J Bil, E Wilczek, GM Wilczynski, M Lekka, PJ Engelberts, ... PLoS medicine 5 (3), e64, 2008 | 159 | 2008 |
| The influence of photodynamic therapy on the immune response D Nowis, T Stokłosa, M Legat, T Issat, M Jakóbisiak, J Gołąb Photodiagnosis and photodynamic therapy 2 (4), 283-298, 2005 | 156 | 2005 |
| Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells E Bolton-Gillespie, M Schemionek, HU Klein, S Flis, G Hoser, T Lange, ... Blood, The Journal of the American Society of Hematology 121 (20), 4175-4183, 2013 | 143 | 2013 |
| Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response A Szokalska, M Makowski, D Nowis, GM Wilczynski, M Kujawa, C Wójcik, ... Cancer research 69 (10), 4235-4243, 2009 | 131 | 2009 |
| BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations T Stoklosa, T Poplawski, M Koptyra, M Nieborowska-Skorska, G Basak, ... Cancer research 68 (8), 2576-2580, 2008 | 128 | 2008 |
| Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice W Lasek, W Feleszko, J Goląb, T Stokłosa, M Marczak, A Dąbrowska, ... Cancer Immunology, Immunotherapy 45, 100-108, 1997 | 103 | 1997 |
| Synthesis and Optical Properties of Tetraaryl‐1,4‐dihydropyrrolo[3,2‐b]pyrroles A Janiga, E Glodkowska‐Mrowka, T Stoklosa, DT Gryko Asian Journal of Organic Chemistry 2 (5), 411-415, 2013 | 100 | 2013 |
| Titin truncating variants in dilated cardiomyopathy–prevalence and genotype-phenotype correlations M Franaszczyk, P Chmielewski, G Truszkowska, P Stawinski, E Michalak, ... PLoS One 12 (1), e0169007, 2017 | 97 | 2017 |
| Immunologia M Jakóbisiak, W Lasek, T Stokłosa, J Gołąb Wydawnictwo Naukowe PWN, 2020 | 91 | 2020 |
| Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF J Goląb, G Wilczyński, R Zagożdżon, T Stoklosa, A Dąbrowska, ... British journal of cancer 82 (8), 1485-1491, 2000 | 91 | 2000 |
| Bright, color-tunable fluorescent dyes based on π-expanded diketopyrrolopyrroles M Grzybowski, E Glodkowska-Mrowka, T Stoklosa, DT Gryko Organic letters 14 (11), 2670-2673, 2012 | 85 | 2012 |
| Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice D Nowis, M Bugajski, M Winiarska, J Bil, A Szokalska, P Salwa, T Issat, ... BMC cancer 8, 1-12, 2008 | 85 | 2008 |
| The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells M Kusio-Kobialka, P Podszywalow-Bartnicka, P Peidis, ... Cell Cycle 11 (21), 4069-4078, 2012 | 82 | 2012 |